ClinConnect ClinConnect Logo
Search / Trial NCT03216564

An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes

Launched by HAMAD MEDICAL CORPORATION · Jul 11, 2017

Trial Information

Current as of July 16, 2025

Unknown status

Keywords

ClinConnect Summary

The investigators propose to test the efficacy and safety of a combined regimen of calcitriol and angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in type 2 diabetes subjects with albuminuria. In the proposed study, the bioactive form of vitamin D (calcitriol) is being used for its ability to synergize with ACEI or ARB and prevent renal disease progression. The study expands on preliminary studies demonstrating a reduction in proteinuria with vitamin D analogue treatment, in subjects with both diabetic as well as non-diabetic kidney disease.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age greater than or equal to 18 years and less than 80 years
  • 2. Diagnosis of T2DM requiring treatment with at least one oral hypoglycaemic medication or insulin 2.1. Subjects will be considered to have established T2DM if the diagnosis of diabetes has been made and the subjects were treated with insulin or an oral hypoglycaemic agent for at least 6 months after diagnosis 2.2. Subjects will be considered to have newly established T2DM if the diagnosis of diabetes was diagnosed with a fasting plasma glucose ≥ 7 mmol/L (126 mg/dL) or haemoglobin A1c is \>6.5% in the past 6 months
  • 3. Documented albuminuria defined as a presence of albuminuria on two occasions in the last six months:
  • 3.1. Albumin ≥ 30 mg/24 hour in a 24 hour urine collection, or 3.2. Albumin ≥ 20 μg/min in a short-time urine collection, or 3.3. Albumin ≥ 30 mg/L in a spot urine sample, or 3.4. A spot-urine albumin-creatinine ration (ACR) ≥ 30 mg/g creatinine (≥ 2.5 mg/mmol creatinine in men, ≥ 3.5 mg/mmol creatinine in women)
  • 4. Estimated glomerular filtration rate (eGFR) using the 4-variable Modification of Diet in Renal Disease (MDRD) equation of ≥ 25 mL/min/1.73 m2
  • Exclusion Criteria:
  • 1. If female, positive pregnancy test or planning pregnancy in the subsequent 12 months
  • 2. Pregnant
  • 3. Breastfeeding
  • 4. Corrected serum calcium ≥ 2.62 mmol/L
  • 5. Serum Potassium \> 5.2 mmol/L if not on ACEI or ARB; Serum Potassium \> 6.0 mmol/L if on ACEI or ARB
  • 6. 25-hydroxyvitamin D (25-OH Vit D) \> 80 ng/mL
  • 7. PTH \> 200 pg/mL
  • 8. Poorly controlled hypertension defined as systolic blood pressure ≥ 180 mm Hg or diastolic blood pressure ≥ 110 mm Hg
  • 9. Systolic blood pressure (SBP) ≤ 110 mm Hg
  • 10. History of kidney stones
  • 11. History of severe chronic disease (e.g. chronic liver disease)
  • 12. Active malignancy
  • 13. Recent diagnosis of acute renal failure within 3 months of screening visit
  • 14. Likelihood of renal replacement therapy within 1 year

About Hamad Medical Corporation

Hamad Medical Corporation (HMC) is a leading healthcare provider in Qatar, dedicated to delivering high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, HMC focuses on innovative healthcare solutions that enhance patient outcomes and contribute to the global medical knowledge base. With a robust infrastructure and a commitment to ethical research practices, HMC collaborates with local and international partners to conduct trials across various therapeutic areas, aiming to address pressing health challenges and improve the standard of care within the community. Through its research initiatives, HMC strives to foster a culture of scientific inquiry and evidence-based medicine, ultimately benefiting patients and the healthcare system at large.

Locations

Doha, , Qatar

Patients applied

0 patients applied

Trial Officials

Muhammad Asim, MB BS

Principal Investigator

Hamad Medical Corporation

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials